Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million
HTDS' Chinese subsidiary, Mellow Hope, is the exclusive agent of Zhejiang Tianyuan Bio-pharmaceutical for International marketing and sales. Zhejiang Tianyuan Bio-pharmaceutical has been granted a H1N1 license on
Novartis reports that it has made the purchase of a majority interest in Zhejiang Tianyuan through proposed acquisition of a majority stake for
Tianyuan is a privately-owned vaccine company offering a range of marketed vaccine products in
About Hard To Treat Diseases (HTDS)
Mellow Hope is
In Serbia the company's primary focus involves the enhancement and modification of existing approved drugs such as "Virazole" for the purpose of chemical repair of damage to the CNS (central nervous system), MS (Multiple Sclerosis), SARS, Hepatitis C and HIV.
To receive future updates, via email including quarterly newsletters and company updates which may not be newsworthy, however important to the reader and followers of the company please sign up today for free at www.minamargroup.com/updates
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact email@example.com; For any corporate matters, please contact www.minamargroup.com/helpdesk; For any retail investor relations matters, please contact www.minamargroup.net/helpdesk, (IR); For (M&A) and Corporate Matters www.minamargroup.com
SOURCE Hard to Treat Diseases